The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictors of complete pathological response (pT0) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC).
Venkata Kiran Pokuri
No relevant relationships to disclose
Johar R. Syed
No relevant relationships to disclose
Zhengyu Yang
No relevant relationships to disclose
Erinn P. Field
No relevant relationships to disclose
Roberto Pili
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Ellis Glenn Levine
No relevant relationships to disclose
Donald L. Trump
No relevant relationships to disclose
Alan Hutson
No relevant relationships to disclose
Khurshid Guru
Employment or Leadership Position - Simulated Surgical Systems
Saby George
Consultant or Advisory Role - Algeta/Bayer; Astellas Pharma; AVEO; Novartis; Sanofi
Research Funding - GlaxoSmithKline